NeoGenomics, Inc.
HealthcareNASDAQ:NEO · NASDAQ Capital Market
-$0.32 today
Vol 1.48M · Avg 1.87M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-12.9%
avg -4.3%
ROIC
-5.1%
avg -2.3%
ROA
-7.9%
avg -2.5%
Analysis
ROIC is currently the strongest return metric at -5.1% versus its period average of -2.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Anthony Zook | Chief Executive Officer & Director | $1.35M | — | 65 | $133,111.00 | 0.51% |
Warren Stone | President & Chief Operating Officer | $1.32M | — | 53 | $167,815.00 | 0.64% |
Alicia Olivo | Executive Vice President of Business Development, General Counsel & Corporate Secretary | $800,154.00 | — | 42 | $93,567.00 | 0.36% |
Gary Passman | Chief People & Culture Officer | $693,324.00 | — | — | — | — |
Elizabeth A. Floegel | Chief Digital & Information Officer | $38,628.00 | — | 50 | $91,422.00 | 0.35% |
Clarence Cooper | Vice President of Compliance & Privacy | — | — | — | — | — |
Kendra Sweeney | Vice President of Investor Relations & Communications | — | — | — | — | — |
Abhishek Jain | Executive VP & CFO | — | — | 50 | $0.00 | <0.01% |
Gregory D. Aunan | Senior Vice President & Chief Accounting Officer | — | — | 57 | $26,462.00 | 0.10% |
Kareem Saad | Head of Strategy, Business Development & Transformation | — | — | 47 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$212,275.60
Sells
3
$587,589.90
Net Sentiment
$375,314.30
Net selling
Most Active
TETRAULT LYNN A.
1 transactions
Analysis
Insiders reported 2 buys worth $212,275.60 and 3 sells worth $587,589.90 over the last 12 months. That adds up to net selling of $375,314.30. TETRAULT LYNN A. was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +18.6% | +17.5% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +18.6% over three years. Forward estimates point to Revenue at +17.5% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
$520.97M
Alpha Teknova, Inc.
NASDAQ:TKNO
$225.18M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Sanara MedTech Inc.
NASDAQ:SMTI
$190.70M
Stereotaxis, Inc.
AMEX:STXS
$179.84M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
Exagen Inc.
NASDAQ:XGN
$112.83M
MDxHealth S.A.
MDXH
$27.85M
Who manages NEO?
NeoGenomics, Inc. (NEO) lists 10 active executives. The top listed executive is Anthony Zook, Chief Executive Officer & Director.
Are NEO insiders buying or selling?
Recent insider activity shows net buying of $31.09M.
Explore More
Continue the stock analysis
Jump to another research area for this company.